Genetics as a tool to improve cancer outcomes: Ethics and policy

Nature Reviews Cancer

Volumn 6, Issue 6, 2006, Pages 476-482

  Burke, Wylie ^a   Press, Nancy ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER GENETICS; CANCER RISK; COLORECTAL CANCER; ETHICS; FAMILY HISTORY; GENE MUTATION; GENETIC COUNSELING; GENETIC PROCEDURES; GENETIC RISK; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HEALTH SERVICE; HUMAN; MASTECTOMY; OUTCOME ASSESSMENT; OVARY CANCER; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS;

BIOETHICS; FEMALE; GENETIC COUNSELING; GENETIC PREDISPOSITION TO DISEASE; GENETIC RESEARCH; GENETIC SCREENING; HUMANS; MALE; NEOPLASMS; PUBLIC POLICY; TREATMENT OUTCOME;

EID: 33745684524     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc1890     Document Type: Review

References (56)

1. Petrucelli, N., Daly, M. B., Culver, J., Lecy-Lahad, E. & Feldman, G. L. BRCA1 and BRCA2 hereditary breast/ ovarian cancer. GeneReviews [online], http://www. genetests.org/servlet/access?db=geneclinics&site=gt &id=8888891&key=u2buBbQW4OfpB&gry=&fcn =y&fw= DeB0&filename=/profiles/brca1/index.html (2005).
2. Schneider, K. A. & Li, F. Li-Fraumeni syndrome. GeneReviews [online], http://www.genetests.org/ servlet/access?db=geneclinics&site=gt&id=8888 891&key=u2buBbQW4OfpB&gry=&fcn=y&fw= wVIP&filename=/ profiles/li-fraumeni/index.html (2004).
3. Zhuk, K., Stein, J. L. & Eng, C. PTEN hamartoma tumor syndrome (PHTS). GeneReviews [online], http:// www.genetests.org/servlet/access?db= geneclinics&sit e=gt&id=8888891&key=u2buBbQW4OfpB&gry= &fcn=y&fw=fpbf&filename=/profiles/phts/index. html (2006).
4. Weisner, G. & Snow-Bailey, K. Multiple endocrine neoplasia type 2. GeneReviews [online], http://www. genetests.org/servlet/access?db= geneclinics&site=gt &id=8888891&key=u2buBbQW4OfpB&gry=&fcn =y&fw=i4KT&filename=/profiles/men2/index.html (2005).
5. Solomon, C. & Burt, R. W. APC-associated polyposis conditions. GeneReviews [online], http://www.genetests. org/servlet/access?db= geneclinics&site=gt&id=888 8891&key=u2buBbQW4OfpB&gry=&fcn= y&fw=Lw hz&filename=/profiles/fap/index.html (2005).
6. Kohlmann, W. & Gruber, S. B. Hereditary nonpolyposis colon cancer. GeneReviews [online], http:// www.genetests.org/servlet/access?db= geneclinics&sit e=gt&id=8888891&key=u2buBbQW4OfpB&gry= &fcn=y&fw=NvB-&filename=/profiles/hnpcc/index. html (2004).
7. Beauchamp, T. L. & Childress, J. F. Principles of Biomedical Ethics 5th edn (Oxford Univ. Press, New York, 2001).
8. Pellegrino, E. D. Toward a reconstruction of medical morality. Am. J. Bioeth. 6, 65-71 (2006).
9. Levi, B. H. Four approaches to doing ethics. J. Med. Philos. 21, 7-39 (1996).
10. Mackenzie, C. & Stoljar, N. (eds) Relational Autonomy: Feminist Perspectives on Autonomy, Agency, and the Social Self (Oxford Univ. Press, Oxford, 2000).
11. O'Neill, V. Autonomy and Trust in Bioethics. (Cambridge Univ. Press, Cambridge, 2002).
12. Tauber, A. I. A philosophical approach to rationing. Med. J. Aust. 178, 454-456 (2003).
13. Ford, D. et al. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 343, 692-695 (1994).
14. Burke, W. et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. 1. Hereditary nonpolyposis colon cancer. JAMA 277, 915-919 (1997).
15. Statement of the American Society of Human Genetics on genetic testing for breast/ovarian cancer prevention. Am. J. Hum. Genet. 55, i-iv (1994).
16. National Advisory Council for Human Genome Research. Statement on use of DNA testing for presymptomatic identification of cancer risk. JAMA 271, 785 (1994)
17. Antoniou, A. et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am. J. Hum. Genet. 72, 1117-1130 (2003).
18. Narod, S. A. Modifiers of risk of hereditary breast and ovarian cancer. Nature Rev. Cancer 2, 113-122 (2002).
19. Thompson, D. & Easton, D. Variation in cancer risks by mutation position in BRCA2 carriers. Am. J. Hum. Genet. 68, 410-419 (2001).
20. Thompson, D., Easton, D. & the Breast Cancer Linkage Consortium. Variation in BRCA1 cancer risks by mutation position. Cancer Epidemiol. Biomarkers Prev. 11, 329-336 (2002).
21. Nelson, H. D. et al. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force. Ann. Intern. Med. 143, 362-379 (2005).
22. ACR Practice Guideline for the Performance of Magnetic Resonance Imaging (MRI) of the Breast. American College of Radiology [online], http://www. acr.org/s_acr/bin.asp?CID=549&DID=17775&DOC =FILE.PDF (2004).
23. Patenaude, A. F. Genetic Testing for Cancer: Psychological Approaches for Helping Patients and Families (American Psychological Association, Washington DC, 2005).
24. Loman, N. et al. Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early onset breast cancer. J. Natl Cancer Inst. 93, 1188-1189 (2001).
25. Narod, S. A. et al. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J. Natl Cancer Inst. 94, 1773-1779 (2002).
26. King, M.-C. et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2. JAMA 286, 2251-2256 (2001).
27. Freund, C. L., Clayton, E. W. & Wilfond, B. S. Natural settings trials - improving the introduction of clinical genetic tests. J. Law Med. Ethics 32, 106-110 (2004).
28. Lapham, E. V., Kozma, C. & Weiss, J. O. Genetic discrimination: perspectives of consumers. Science 274, 621-624 (1996).
29. Billings, P. R. et al. Discrimination as a consequence of genetic testing. Am. J. Hum. Genet. 50, 476-482 (1992).
30. Low, L., King, S. & Wilkie, T. Genetic discrimination in life insurance: empirical evidence from a cross sectional survey of genetic support groups in the United Kingdom. BMJ 317, 1632-1635 (1998).
31. Hall, M. A. & Rich, S. S. Laws restricting health insurers' use of genetic information: impact on genetic discrimination. Am. J. Hum. Genet. 66, 293-307 (2000).
32. Kinney, A. Y., Emery, G., Dudley, W. N. & Croyle, R. T. Screening behaviors among African American women at high risk for breast cancer: do beliefs about god matter? Oncol. Nurs. Forum. 29, 835-843 (2002).
33. Marteau, T. M. & Lerman, C. Genetic risk and behavioural change. BMJ 322, 1056-1059 (2001).
34. Loader, S., Shield, C. G. & Rowley, P. T. Impact of genetic testing for breast-ovarian cancer susceptibility. Genet. Test 8, 1-12 (2004).
35. Skinner, M. A. et al. Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. N. Engl. J. Med. 353, 1105-1113 (2005).
36. Garber, J. E. & Offit, K. Hereditary cancer predisposition syndromes. J. Clin. Oncol. 23, 276-292 (2005).
37. US Preventive Services Task Force. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement. Ann. Intern. Med. 143, 355-361 (2005).
38. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J. Clin. Oncol. 21, 2397-2406 (2003).
39. Pate v. Threlkel 661 So.2d 278 (Florida, 1995).
40. Safer v. Pack 677 A2d 1188 (New Jersey, 1996).
41. The American Society of Human Genetics Social Issues Subcommittee on Familial Disclosure. American Society of Human Genetics statement: Professional disclosure of familial genetic information. Am. J. Hum. Genet. 62, 474-483 (1998).
42. Hakimian, R. Disclosure of Huntington's disease to family members: the dilemma of known but unknowing parties. Genet. Test. 4, 359-364 (2000).
43. Annas, G. J. Genetic prophecy and genetic privacy - can we prevent the dream from becoming a nightmare? Am. J. Public Health 85, 1196-1197 (1995).
44. Genetic counseling. Am. J. Hum. Genet. 27, 240-242 (1975).
45. Wainberg, S. & Husted, J. Utilization of screening and preventive surgery among unaffected carriers of a BRCA1 or BRCA2 gene mutation. Cancer Epidemiol. Biomarkers Prev. 13, 1989-1995 (2004).
46. Press, N. et al. 'That's like chopping off a finger because you're afraid it might get broken': disease and illness in women's views of prophylactic mastectomy. Soc. Sci. Med. 61, 1106-1117 (2005).
47. Brody, H. Transparency: informed consent in primary care. Hastings Cent. Rep. 19, 5-9 (1989).
48. Gwyn, K., Vernon, S. W. & Conoley, P. M. Intention to pursue genetic testing for breast cancer among women due for screening mammography. Cancer Epidemiol. Biomarkers Prev. 12, 96-102 (2003).
49. Khoury, M. J. et al. Challenges in communication about genetics: a public health approach. Genet. Med. 2, 198-201 (2000).
50. McCabe, L. L. & McCabe, E. R. Direct-to-consumer genetic testing: access and marketing. Genet Med. 6, 58-59 (2004).
51. Centers for Medicare and Medicaid Services. Emergency Medical Treatment and Labor Act (EMTALA) resource. CMS [online], http://www.cms.hhs. gov/EMTALA (2005).
52. Centers for Disease Control and Prevention. National Breast and Cervical Cancer Early Detection Program. CDC [online], http://www.cdc.gov/cancer/nbccedp (2006).
53. Comments by Dr. Francis S. Collins Regarding the Passage of Genetic Information Nondiscrimination Act of 2005 (S. 306). National Human Genome Research Institute [online], http://www.genome.gov/13014311 (2005).
54. Burke, W. & Zimmern, R. L. Ensuring the appropriate use of genetic tests. Nature Rev. Genet. 5, 955-959 (2004).
55. Field, M. J., Lohr, K. N. & Committee on Clinical Practice Guidelines. Guidelines for Clinical Practice: From Development to Use. (Institute of Medicine, Washington DC, 1992).
56. Centers for Disease Control and Prevention. Evaluation of Genetic Testing. CDC [online], http:// www.cdc.gov/genomics/gtesting/egapp.htm (2006).